Should You Invest in Merck & Co., Inc [NYSE: MRK]?

Shares of Merck & Co., Inc. [NYSE: MRK] jumped 7% at the time of writing on Friday after the firm disclosed that Molnupiravir has substantially decreased the risk of hospitalization or death at a scheduled interim analysis of the Phase III MOVe-OUT study in at-risk, non-hospitalized adult sufferers with mild-to-severe COVID-19.

Presently, the world is in dire need of more and more treatment to fight with ongoing pandemic which has affected the lives of millions of people all around the globe. This news of the firm’s COVID-19 vaccine is new hope for sufferers all around the globe. The firm disclosed that the interim results of Molnupiravir which is an investigational oral antiviral medicine ha assured the firm that it will help the world in its fight with COVID-19.

Phase III MOVe-OUT Study

It has been witnessed by the firm that at the interim analysis, Molnupiravir decreased the risk of hospitalization or death by nearly 50%. Furthermore, 7.3% of sufferers who got Molnupiravir were either hospitalized or died through Day 29 after randomization, compared with 14.1% of placebo-treated patients. Through Day 29, no deaths were witnessed in sufferers who got Molnupiravir, as compared to 8 deaths in sufferers who got a placebo.

The scheduled interim analysis assessed data from 775 sufferers who were initially registered in the Phase III MOVe-OUT trial on or prior to Aug. 5, 2021. At the time of the decision to stop recruitment based on the convincing interim efficacy results, the trial was considering full recruitment of the Phase III sample size of 1,550 sufferers, with more than 90% of the intended sample size already registered.

Merck Future Plan

Merck is intending to file an application for Emergency Use Authorization (EUA) to the U.S. FDA as soon as possible based on these outcomes. The firm is also intending to submit marketing applications to other regulatory bodies all around the world. In expectation of the results from MOVe-OUT, Merck has been creating Molnupiravir at risk. Merck anticipates producing 10 million courses of medicine by the end of 2021, with more doses likely to be created in 2022.